Background
Methods
Design of care bundles as proxies for composite measures
· | A care bundle should relate to a specific clinical condition |
· | A care bundle should have a minimum of three components |
· | Care bundle components should describe a specific, measurable action |
· | Delivery of every component should be possible for the practice team. |
· | Bundle components should be relevant to all patients with that condition. |
· | Components must be repeatable, rather than ‘one-off’ actions. |
· | Components should not duplicate or be a necessary part of each other |
Measuring care bundle compliance
Setting and sample size
Data collection
Statistical analysis
Results
Care bundles (composite measures) and indicators
Secondary prevention of Coronary Heart Disease (CHD)
| |
The percentage of patients with coronary heart disease: | |
CHD6 | …in whom the last blood pressure reading (measured in the previous 15 months) is 150/90 or less |
CHD8 | …whose last measured total cholesterol (measured in the previous 15 months) is 5 mmol/l or less |
CHD9 | …with a record in the previous 15 months that aspirin, an alternative anti-platelet therapy, or an anti-coagulant is being taken (unless a contraindication or side-effects are recorded) |
CHD10 | …who are currently treated with a beta blocker (unless a contraindication or side-effects are recorded) |
CHD11 | …a history of myocardial infarction (diagnosed after 1 April 2003) who are currently treated with an ACE inhibitor or Angiotensin II antagonist |
CHD12 | …who have a record of influenza immunisation in the preceding 1 September to 31 March |
Chronic kidney disease (CKD)
| |
The percentage of patients on the CKD register: | |
CKD3 | …whom the last blood pressure reading, measured in the previous 15 months, is 140/85 or less |
CKD5 | …with hypertension and proteinuria who are treated with an angiotensin converting enzyme inhibitor (ACE – I) or angiotensin receptor blocker (ARB) (unless a contraindication or side effects are recorded) |
CKD6 | …whose notes have a record of a urine albumin: creatinine ratio (or protein: creatinine ratio) test in the previous 15 months |
Diabetes mellitus (DM)
| |
The percentage of patients with diabetes: | |
DM2 | …whose notes record BMI in the previous 15 months |
DM24 | …in whom the last HbA1c is 8 or less (or equivalent test/reference range depending on local laboratory) in the previous 15 months |
DM9 | …with a record of the presence or absence of peripheral pulses in the previous 15 months |
DM10 | …with a record of neuropathy testing in the previous 15 months |
DM12 | …in whom the last blood pressure is 145/85 or less |
DM15 | …with a diagnosis of proteinuria or micro-albuminuria who are treated with ACE inhibitors (or A2 antagonists) |
DM17 | …whose last measured total cholesterol within the previous 15 months is 5 mmol/l or less |
DM18 | …who have had influenza immunisation in the preceding 1 September to 31 March |
Chronic obstructive pulmonary disease (COPD)
| |
The percentage of patients with COPD: | |
COPD10 | …with a record of FeV1 in the previous 15 months |
COPD13 | …who have had a review, undertaken by a healthcare professional, including an assessment of breathlessness using the MRC dyspnoea score in the preceding 15 months |
COPD8 | …who have had influenza immunisation in the preceding 1 September to 31 March |
Stroke and transient ischaemic attack (Stroke/TIA)
| |
The percentage of patients with: | |
STROKE6 | …a history of TIA or stroke in whom the last blood pressure reading (measured in the previous 15 months) is 150/90 or less |
STROKE8 | …TIA or stroke whose last measured total cholesterol (measured in the previous 15 months) is 5 mmol/l or less |
STROKE12 | … with a stroke shown to be non-haemorrhagic, or a history of TIA, who have a record that an anti-platelet agent (aspirin, clopidogrel, dipyridamole or a combination), m or an anti-coagulant is being taken (unless a contraindication or side-effects are recorded) |
STROKE10 | …TIA or stroke who have had influenza immunisation in the preceding 1 September to 31 March |
Response rate and demographics
Clinical conditions & Indicators |
Payment
| Participating general practices – codes A-I | Total | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Points*
|
Threshold
| A | B | C | D | E | F | G | H | I | ||
All patients = n
|
Min-Max
|
7613
|
2277
|
2893
|
4567
|
12850
|
10939
|
3507
|
4600
|
7702
|
56948
| |
CKD n(%)
| 246 (3.2) | 111 (4.9) | 86 (3.0) | 151 (3.3) | 321 (2.5) | 535 (4.9) | 97 (2.8) | 172 (3.7) | 194 (2.5) | 1913 (3.4) | ||
CKD3 |
11
|
40-70%
| 186 (75.2) | 72 (64.9) | 64 (74.4) | 116 (76.8) | 255 (79.4) | 421 (78.7) | 85 (87.6) | 85 (87.6) | 143 (73.7) |
1472 (76.9)
|
CKD5 |
9
|
40-80%
| 245 (99.6) | 110 (99.1) | 86 (100) | 151 (100) | 316 (98.4) | 532 (99.4) | 96 (99.0) | 96 (99.0) | 192 (99.0) |
1890 (98.8)
|
CKD6 |
6
|
40-80%
| 211 (85.8) | 111 (100) | 85 (98.8) | 136 (90.1) | 282 (87.9) | 469 (87.7) | 90 (92.8) | 90 (92.8) | 171 (88.1) |
1707 (89.2)
|
Overall
|
158 (64.2)
|
71 (64.0)
|
64 (74.4)
|
105 (69.5)
|
225 (70.1)
|
380 (71.0)
|
79 (81.4)
|
79 (81.4)
|
129 (66.5)
|
1320 (69.0)
| ||
STROKE/TIA n(%)
| 173 (2.3) | 62 (2.7) | 75 (2.6) | 100 (2.2) | 309 (2.4) | 248 (2.3) | 67 (1.9) | 112 (2.4) | 129 (1.7) | 1275 (2.2) | ||
STR6 |
5
|
40-70%
| 165 (95.4) | 52 (83.9) | 67 (89.3) | 90 (90.0) | 288 (93.2) | 226 (91.1) | 56 (83.6) | 105 (93.8) | 118 (91.5) |
1167 (91.5)
|
STR8 |
5
|
40-60%
| 158 (91.3) | 48 (77.4) | 60 (80.0) | 81 (81.0) | 283 (91.6) | 213 (85.9) | 58 (86.6) | 95 (84.8) | 110 (85.3) |
1106 (86.7)
|
STR12 |
4
|
40-90%
| 166 (96.0) | 60 (96.8) | 72 (96.0) | 96 (96.0) | 305 (98.7) | 235 (94.8) | 65 (97.0) | 108 (96.4) | 125 (96.9) |
1232 (96.6)
|
STR10 |
2
|
40-85%
| 151 (87.3) | 59 (95.2) | 73 (97.3) | 96 (96.0) | 293 (94.8) | 234 (94.4) | 61 (91.0) | 104 (92.9) | 124 (96.1) |
1195 (93.7)
|
Overall
|
129 (74.6)
|
32 (51.6)
|
52 (69.3)
|
66 (66.6)
|
256 (82.8)
|
179 (72.2)
|
43 (64.2)
|
84 (75.0)
|
96 (74.4)
|
945 (74.1)
| ||
Diabetes Mellitus n(%)
| 275 (3.6) | 120 (5.3) | 159 (5.5) | 156 (3.4) | 520 (4.0) | 458 (4.2) | 163 (4.6) | 181 (3.9) | 366 (4.8) | 2398 (4.2) | ||
DM2 |
3
|
40-90%
| 265 (96.4) | 120 (100) | 159 (100) | 151 (96.8) | 506 (97.3) | 449 (98.0) | 159 (97.5) | 175 (96.7) | 356 (97.3) |
2340 (97.6)
|
DM24 |
8
|
40-70%
| 250 (90.9) | 95 (79.2) | 140 (88.1) | 133 (85.3) | 432 (83.1) | 359 (78.4) | 136 (83.4) | 148 (81.8) | 296 (80.9) |
1989 (82.9)
|
DM9 |
3
|
40-90%
| 244 (88.7) | 119 (99.2) | 147 (92.5) | 151 (96.8) | 475 (91.3) | 421 (91.9) | 159 (97.5) | 165 (91.2) | 353 (96.4) |
2234 (93.2)
|
DM10 |
3
|
40-90%
| 244 (88.7) | 119 (99.2) | 147 (92.5) | 150 (96.2) | 475 (91.3) | 422 (92.1) | 159 (97.5) | 166 (91.7) | 351 (95.9) |
2233 (93.1)
|
DM12 |
18
|
40-60%
| 244 (88.7) | 105 (87.5) | 144 (90.6) | 118 (75.6) | 459 (88.3) | 375 (81.9) | 133 (81.6) | 166 (91.7) | 329 (89.9) |
2060 (85.9)
|
DM13 |
3
|
40-90%
| 253 (92.0) | 119 (99.2) | 154 (96.9) | 140 (89.7) | 484 (93.1) | 426 (93.0) | 149 (91.4) | 153 (84.5) | 345 (94.3) |
2244 (93.6)
|
DM22 |
3
|
40-90%
| 269 (97.8) | 120 (100.) | 157 (98.7) | 151 (96.8) | 506 (97.3) | 442 (96.5) | 160 (98.2) | 174 (96.1) | 361 (98.6) |
2346 (97.8)
|
DM15 |
3
|
40-80%
| 267 (97.1) | 116 (96.7) | 156 (98.1) | 156 (100) | 515 (99.0) | 458 (100) | 160 (98.2) | 180 (99.4) | 359 (98.1) |
2363 (98.5)
|
DM17 |
6
|
40-70%
| 253 (92.0) | 109 (90.8) | 145 (91.2) | 147 (94.2) | 475 (91.3) | 396 (86.5) | 139 (85.3) | 155 (85.6) | 313 (85.5) |
2132 (88.9)
|
DM18 |
3
|
40-85%
| 246 (89.5) | 118 (98.3) | 153 (96.2) | 139 (89.1) | 492 (94.6) | 419 (91.5) | 147 (90.2) | 162 (89.5) | 351 (95.9) |
2227 (92.9)
|
Overall
|
166 (60.4)
|
75 (62.5)
|
103 ( 64.8)
|
84 (53.8)
|
339 (65.2)
|
239 (52.2)
|
82 (50.3)
|
100 (55.2)
|
213 (58.2)
|
1401 (58.4)
| ||
Sec prev. of CHD n(%)
| 317 (4.2) | 128 (5.6) | 178 (6.2) | 204 (4.5) | 547 (4.3) | 546 (5.0) | 189 (5.4) | 203(4.4) | 327 (4.2) | 2639 (4.6) | ||
CHD6 |
17
|
40-70%
| 300 (94.6) | 118 (92.2) | 162 (91.0) | 174 (85.3) | 524 (95.8) | 495 (90.7) | 166 (87.8) | 187 (92.1) | 312 (95.4) |
2438 (92.4)
|
CHD8 |
17
|
40-70%
| 294 (92.7) | 103 (80.5) | 134 (75.3) | 186 (91.2) | 510 (93.2) | 464 (85.0) | 155 (82.0) | 162 (79.8) | 308 (94.2) |
2316 (87.8)
|
CHD9 |
7
|
40-90%
| 293 (92.4) | 120 (93.8) | 172 (96.6) | 199 (97.5) | 541 (98.9) | 511 (93.6) | 172 (91.0) | 195 (96.1) | 319 (97.6) |
2522 (95.6)
|
CHD10 |
7
|
40-60%
| 295 (93.1) | 91 (71.1) | 125 (70.2) | 184 (90.2) | 504 (92.1) | 402 (73.6) | 131 (69.3) | 149 (73.4) | 300 (91.7) |
2181 (82.6)
|
CHD11 |
7
|
40-80%
| 312 (98.4) | 128 (100) | 178 (100) | 202 (99.0) | 540 (98.7) | 539 (98.7) | 187 (98.9) | 202 (99.5) | 325 (99.4) |
2613 (99.0)
|
CHD12 |
7
|
40-90%
| 293 (92.4) | 122 (95.3) | 172 (96.6) | 193 (94.6) | 526 (96.2) | 524 (96.0) | 178 (94.2) | 186 (91.6) | 313 (95.7) |
2507 (95.0)
|
Overall
|
228 (71.9)
|
62 (48.4)
|
85 (47.8)
|
118 (57.8)
|
348 (63.6)
|
354 (64.8)
|
86 (45.5)
|
71 (35.0)
|
211 (64.5)
|
1690 (64.0)
| ||
COPD n(%)
| 163 (2.1) | 72 (3.2) | 92 (3.2) | 36 (0.8) | 286 (2.2) | 298 (2.7) | 55 (1.6) | 176 (3.8) | 142 (1.8) | 1320 (2.3) | ||
COPD10 |
7
|
40-70%
| 152 (93.3) | 69 (95.8) | 85 (92.4) | 32 (88.9) | 254 (88.8) | 273 (91.6) | 52 (94.5) | 167 (94.9) | 74 (52.1) |
1158 (87.7)
|
COPD13 |
9
|
50-90%
| 155 (95.1) | 69 (95.8) | 85 (92.4) | 34 (94.4) | 270 (94.4) | 280 (94.0) | 54 (98.2) | 170 (96.6) | 137 (96.5) |
1254 (95.0)
|
COPD8 |
6
|
40-85%
| 150 (92.0) | 72 (100) | 88 (95.7) | 35 (97.2) | 270 (94.4) | 278 (93.3) | 53 (96.4) | 166 (94.3) | 134 (94.4) |
1246 (94.4)
|
Overall
|
140 (85.9)
|
69 (95.8)
|
83 (90.2)
|
30 (83.3)
|
231 (80.8)
|
254 (85.2)
|
50 (90.9)
|
157 (89.2)
|
68 (47.9)
|
1082 (82.0)
|